Author
Listed:
- Aurélien Mattuizzi
(Bordeaux University Hospital)
- Fanny Sauvestre
(Bordeaux University Hospital)
- Tiphaine Fargeix
(Bordeaux University Hospital
Bordeaux University)
- Eoghann White
(Bordeaux University)
- Claire Leibler
(Bordeaux University
Bordeaux University Hospital)
- Marine Cargou
(Bordeaux University Hospital)
- Nathalie Dugot-Senant
(TBM-Core US 005)
- Isabelle Douchet
(Bordeaux University)
- Dorothée Duluc
(Bordeaux University)
- Cécile Bordes
(Bordeaux University
Bordeaux University Hospital)
- Marie-Élise Truchetet
(Bordeaux University
Bordeaux University Hospital)
- Christophe Richez
(Bordeaux University
Bordeaux University Hospital)
- Édouard Forcade
(Bordeaux University
Bordeaux University Hospital)
- Pierre Duffau
(Bordeaux University
Bordeaux University Hospital)
- Jean-François Viallard
(Bordeaux University Hospital)
- Loïc Sentilhes
(Bordeaux University Hospital
Bordeaux University)
- Patrick Blanco
(Bordeaux University
Bordeaux University Hospital)
- Estibaliz Lazaro
(Bordeaux University Hospital
Bordeaux University)
Abstract
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. Here we show a potential role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI, who have undergone treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases are characterized by the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveils heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples, devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals.
Suggested Citation
Aurélien Mattuizzi & Fanny Sauvestre & Tiphaine Fargeix & Eoghann White & Claire Leibler & Marine Cargou & Nathalie Dugot-Senant & Isabelle Douchet & Dorothée Duluc & Cécile Bordes & Marie-Élise Truch, 2024.
"Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology,"
Nature Communications, Nature, vol. 15(1), pages 1-9, December.
Handle:
RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53591-w
DOI: 10.1038/s41467-024-53591-w
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53591-w. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.